METASTATIC SOLID TUMOURS Clinical Trials

24 clinical trials for METASTATIC SOLID TUMOURS across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AN OPEN-LABEL, PHASE I/II FIRST IN HUMAN, DOSE ESCALATION, OPTIMISATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND ANTI-TUMOR ACTIVITY OF IPN01203 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON OR AFTER IMMUNE CHECKPOINT INHIBITOR THERAPIES — RECRUITING · PHASE1
• A PHASE 1B/2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK5764227 ALONE AND IN COMBINATION IN PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED UNRESECTABLE OR METASTATIC GASTROINTESTINAL SOLID TUMORS — RECRUITING · PHASE1
• A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MK-4700 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS — RECRUITING · PHASE1
• A PHASE 2 OPEN-LABEL BASKET STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED REVERSIBLE TYROSINE KINASE INHIBITOR BAY 2927088 IN PARTICIPANTS WITH METASTATIC OR UNRESECTABLE SOLID TUMORS WITH HER2-ACTIVATING MUTATIONS — RECRUITING · PHASE2
• AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7296682 IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS — RECRUITING · PHASE1
• A PHASE IA/IB DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC 6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION — RECRUITING · PHASE1
• AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSE-ESCALATION AND EXTENSION, PHASE IA/IB STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS — RECRUITING · PHASE1
• A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF SQZ-PBMC-HPV AS MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB IN HLA-A*02+ PATIENTS WITH HPV16+ RECURRENT, LOCALLY ADVANCED OR METASTATIC SOLID TUMORS — RECRUITING · PHASE1
• A PHASE 1 COHORT DOSE-ESCALATION TRIAL TO DETERMINE THE SAFETY, TOLERANCE, MAXIMUM TOLERATED DOSE, AND PRELIMINARY ANTINEOPLASTIC ACTIVITY OF AVID200, A TRANSFORMING GROWTH FACTOR ¿ (TGF¿) INHIBITOR, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES — RECRUITING · PHASE1
• OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS — RECRUITING · PHASE2
• A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB OR NIVOLUMAB MONOTHERAPY IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS OF HIGH TUMOR MUTATIONAL BURDEN (TMB-H) — RECRUITING · PHASE2
• A PHASE II STUDY OF NAVARIXIN (MK-7123) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS — RECRUITING · PHASE2
• A PHASE 2 OPEN-LABEL, MULTI-CENTER STUDY OF BMS-986504 AS MONOTHERAPY AND IN COMBINATION WITH OTHER AGENTS IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS WITH HOMOZYGOUS MTAP DELETION (MOUNTAINTAP-5) — NOT_YET_RECRUITING · PHASE2
• A PHASE I, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7617991 IN HLA-A*02:01-POSITIVE PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC MAGE-A4¿POSITIVE SOLID TUMORS — NOT_YET_RECRUITING · PHASE1
• Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. — COMPLETED · PHASE1
• A PHASE 1 STUDY OF [225AC]-FPI-2059 IN ADULT PARTICIPANTS WITH NTSR1-EXPRESSING ADVANCED, METASTATIC AND/OR RECURRENT SOLID TUMOURS — NOT_YET_RECRUITING · PHASE1
• AN OPEN-LABEL, DOSE ESCALATION, PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS — COMPLETED · PHASE1
• A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-EXPLORATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AMG 650 IN SUBJECTS WITH ADVANCED SOLID TUMORS — COMPLETED · PHASE1
• A PHASE IA/IB, OPEN-LABEL, MULTICENTER, GLOBAL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF XMAB24306 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY OR METASTATIC SOLID TUMORS. — COMPLETED · PHASE1
• AN OPEN-LABEL, MULTICENTER PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7296682, A CD25-TARGETING, T-REGULATORY CELL DEPLETING ANTIBODY IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS. — COMPLETED · PHASE1
• A PHASE II, OPEN LABEL, MULTI-DOSE STUDY OF 89ZR-DF-IAB22M2C (CD* PET TRACER) FOR POSITRON EMISSION TOMOGRAPHY (PET/CT) IN PATIENTS WITH METASTATIC SOLID TUMORS — NOT_YET_RECRUITING · PHASE2
• A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS — COMPLETED · PHASE1
• A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOISE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTIC SOLID TUMORS — COMPLETED · PHASE1
• A PHASE IB, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN. AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN 2 (IL2V), THAT TARGETS CARCINOEMBROYONIC ANTIGEN (CEA), AND ATEZOLIZUMAB, AN ANTIBODY THAT TARGETS PROGRAMMED DEATH-LIGAND 1 (PD-L1), ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS — COMPLETED · PHASE1

Refine this search